iODIN is the first patented osseodisintegration platform for controlled, minimally invasive removal of dental implants compromised by peri-implantitis — preserving bone, enabling re-implantation, and creating a new standard of care.
16 granted EU/US patents valid to 2034+. The only osseodisintegration platform on the market. Strategic IP expansion in progress.
20M+ peri-implantitis cases per year globally. The 2005–2020 implant boom is entering its critical 10–20 year risk window now.
RWTH Aachen University studies demonstrate bone-preserving disintegration. Peer-reviewed publications on record.
IP licensing to strategic partners with recurring pay-per-use royalties, device sales and reusables. Minimal OPEX, flexible organization.
EMA (Class IIb) / FDA (Class II; DeNovo via Q-Sub)
Strategic acquisition by dental OEM, standalone commercialization, or IP-licensing scale-up.
iODIN transforms dental implant removal from a last-resort, high-risk intervention into a standardized, predictable and economically attractive clinical procedure.
From last resort
to standard of care —
atraumatic for patients,
scalable for dentists.
The implant boom of 2005–2020 is entering its 10–20 year risk window. No atraumatic removal technology exists today.
Current removal techniques — trephine, piezo, reverse torque — are high risk, traumatic, partly off-label, destroy surrounding bone and induce titanium splinters. Patient wellbeing and re-implantation potential are severely compromised.
Surgical PI treatment shows 32–44% disease recurrence at 5 years. Up to 45% of affected implants are ultimately lost. No consensus on best reconstructive therapy exists.
Dentists face reputational, psychological and medico-legal barriers when explanting their own implants — leading to delayed intervention and worse patient outcomes.
The growing installed base far outpaces therapeutic innovation. No established clinical standard for atraumatic, reproducible implant removal exists today.
Runs on existing hardware in dental clinics. No new capital equipment required for partners.
Validated algorithms control energy delivery per implant geometry. The technical moat.
Modular connector designs cover all implant geometries. Laser energy propagates through the implant interface.
"iODIN is the long-awaited, missing puzzle piece in the PI-treatment pathway. It is likely to become my favourite player and the new standard of care when it comes to dental implant removal."
The 2005–2020 implant wave is entering its 10–20-year risk window. The global installed base grows at ~8%+ p.a. for the next two decades.
Earlier explantation is emerging as consensus over futile reconstructive therapies (EFP / AAP 2024).
Dentists increasingly see re-implantation as a €2–5k+ revenue opportunity, not a clinical problem to avoid.
Connectivity unlocks scalable pay-per-use models, overcoming capital-investment barriers for practices.
EU MDR, ISO 14971 and PMS frameworks create a de-facto obligation to ensure complication management — iODIN fills that gap.
A new procedural category opens. The first-mover owns the terminology, the training pathway and the reference installed base.
Peri-implantitis treatment total market exceeds €20B globally.
Bull-case scenario, Y10 (Y8 of commercialization). TAM based on PI treatment technology market sizing; SAM based on explantation rate assumptions; SOM assumes 40% iODIN procedure penetration. Detailed assumptions, sources and financial model available upon request.
*CTRT = Counter Torque Ratchet Technique. Detailed technology comparison matrix and sources available upon request.
25+ years in dental and clinical practice, implantology and peri-implantitis treatment. Practice owner with deep firsthand understanding of the clinical problem. Inventor of the iODIN procedure, initiator of RWTH Aachen research, and author of the pivotal peer-reviewed iODIN publication.
25+ years in senior management across life sciences, MedTech and healthcare services. Prior leadership roles at Novartis Germany (Franchise Head), BD (Country Manager), Vifor Fresenius Germany (MD), Diaverum Germany (MD) and Linimed Group (COO). Proven track record in commercialization, business development and P&L management.
Detailed source overview, financial model with scenario assumptions, market sizing and technology documentation available upon request to qualified investors, partners and media.